Pharma BD Deal Intelligence
Incyte to buy blood disorder drug in possibly $2B deal — Incyte plans to acquire Vega Therapeutics, a subsidiary of the 'hub-and-spoke' biotech Star…
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio — Incyte agreed to…
Incyte to Acquire Vega Therapeutics for Up-to-$2B, Growing Hematology Pipeline with Phase III VWD Candidate — Incyte agreed to acquire Vega for up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Incyte agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront in cash plus up to $750 million in sales-based milestones (up to $2.0 billion total), announced June 8, 2026. The deal expands Incyte's hematology portfolio into bleeding disorders via VGA039, a Phase 3 investigational subcutaneous prophylactic antibody for von Willebrand disease — the most common inherited bleeding disorder — with potential to be the first subcutaneous prophylactic option versus current intravenous infusions. Closing expected Q3 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Vega Therapeutics, Inc. (this deal) | 2026 | $2.0B | 68 |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
← Browse all deals · How we score deals
More: 2026 deals · Incyte Corporation deals · Hematology deals